MA46585A - Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib - Google Patents
Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriibInfo
- Publication number
- MA46585A MA46585A MA046585A MA46585A MA46585A MA 46585 A MA46585 A MA 46585A MA 046585 A MA046585 A MA 046585A MA 46585 A MA46585 A MA 46585A MA 46585 A MA46585 A MA 46585A
- Authority
- MA
- Morocco
- Prior art keywords
- trapping
- treatment
- methods
- muscle atrophy
- bone diseases
- Prior art date
Links
- 208000020084 Bone disease Diseases 0.000 title 1
- 206010028289 Muscle atrophy Diseases 0.000 title 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 230000020763 muscle atrophy Effects 0.000 title 1
- 201000000585 muscular atrophy Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410595P | 2016-10-20 | 2016-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46585A true MA46585A (fr) | 2019-08-28 |
Family
ID=62019496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046585A MA46585A (fr) | 2016-10-20 | 2017-10-19 | Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20190330307A1 (fr) |
| EP (1) | EP3528833A4 (fr) |
| JP (1) | JP2019535675A (fr) |
| KR (1) | KR20190071758A (fr) |
| CN (1) | CN109922821A (fr) |
| AU (1) | AU2017345435B2 (fr) |
| CA (1) | CA3039066A1 (fr) |
| CL (1) | CL2019001069A1 (fr) |
| CO (1) | CO2019005115A2 (fr) |
| CR (1) | CR20190247A (fr) |
| EA (1) | EA201990971A1 (fr) |
| IL (1) | IL266032B2 (fr) |
| JO (1) | JOP20190085A1 (fr) |
| MA (1) | MA46585A (fr) |
| MX (1) | MX2019004651A (fr) |
| PE (1) | PE20190743A1 (fr) |
| PH (1) | PH12019500853A1 (fr) |
| SG (2) | SG11201903450YA (fr) |
| TN (1) | TN2019000119A1 (fr) |
| TW (1) | TWI826358B (fr) |
| WO (1) | WO2018075747A1 (fr) |
| ZA (1) | ZA201903105B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3280727T (pt) | 2015-04-06 | 2021-04-23 | Acceleron Pharma Inc | Proteínas de fusão do recetor de braço único do tipo i e tipo ii e respetivas utilizações |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| AU2016246708B2 (en) | 2015-04-06 | 2020-12-24 | Acceleron Pharma Inc. | ALK7:actRIIB heteromultimers and uses thereof |
| CA3039525A1 (fr) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Proteines actriib a variant et leurs utilisations |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| JP7139326B2 (ja) | 2016-11-10 | 2022-09-20 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 |
| US11484573B2 (en) | 2017-11-09 | 2022-11-01 | Keros Therapeutics, Inc. | Activin receptor type IIa variants and methods of use thereof |
| JP7510875B2 (ja) | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
| CN116134049A (zh) * | 2020-02-03 | 2023-05-16 | 阿塞勒隆制药公司 | 变体actriib蛋白及其用途 |
| EP4121088A4 (fr) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics Inc | Procédés d'utilisation de variants de récepteur de l'activine de type iib |
| CA3176735A1 (fr) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Chimeres de type ii du recepteur d'activine et leurs methodes d'utilisation |
| WO2021189006A1 (fr) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Procédés d'utilisation de variants du récepteur de l'activine de type iia |
| US20240181007A1 (en) * | 2021-01-08 | 2024-06-06 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2332977T3 (en) * | 2004-07-23 | 2016-02-29 | Acceleron Pharma Inc | ActRII receptor polypeptides |
| TWI573802B (zh) * | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8501678B2 (en) * | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| WO2013106175A1 (fr) * | 2011-12-19 | 2013-07-18 | Amgen Inc. | Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| KR20180026795A (ko) * | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| CA2773494A1 (fr) * | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Antagonistes d'actriib, et dosage et administration associes |
| CA2779472C (fr) * | 2009-11-03 | 2021-03-16 | Acceleron Pharma Inc. | L'utilisation d'une composition renfermant un polypeptide recepteur d'activine de type iib pour le traitement de steatose hepatique |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| BR112017022658A2 (pt) * | 2015-04-22 | 2018-07-17 | Alivegen Usa Inc | proteína isolada, molécula de ácido nucleico isolada, vetor recombinante, célula hospedeira, método de produção de uma proteína actriib híbrida, composição farmacêutica, métodos de tratamentos de distúrbios relacionados à miostatina ou relacionados à ativina a, de doença de desgaste dos músculos, de doença cardiovascular, de distúrbios metabólicos, de células cancerígenas, de doença renal, de doença inflamatória/autoimune, de uma doença de fibrose, de anemia, da dor, da condição de envelhecimento, de distúrbios ósseos, de um desgaste dos músculos ou distúrbio metabólico ou fibrótico ou inflamatório ou relacionado à ativina em indivíduos, e, método de indução do crescimento das células-tronco para o reparo de tecido ou regeneração do órgão em um indivíduo |
| WO2017192847A1 (fr) * | 2016-05-04 | 2017-11-09 | University Of Cincinnati | Thérapies de la fertilité femelle |
| CA3039525A1 (fr) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Proteines actriib a variant et leurs utilisations |
| JP7510875B2 (ja) * | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
-
2017
- 2017-06-16 JO JOP/2019/0085A patent/JOP20190085A1/ar unknown
- 2017-10-18 TW TW106135727A patent/TWI826358B/zh active
- 2017-10-19 EA EA201990971A patent/EA201990971A1/ru unknown
- 2017-10-19 AU AU2017345435A patent/AU2017345435B2/en active Active
- 2017-10-19 WO PCT/US2017/057351 patent/WO2018075747A1/fr active Application Filing
- 2017-10-19 MX MX2019004651A patent/MX2019004651A/es unknown
- 2017-10-19 TN TNP/2019/000119A patent/TN2019000119A1/en unknown
- 2017-10-19 JP JP2019521409A patent/JP2019535675A/ja active Pending
- 2017-10-19 CR CR20190247A patent/CR20190247A/es unknown
- 2017-10-19 MA MA046585A patent/MA46585A/fr unknown
- 2017-10-19 EP EP17861941.7A patent/EP3528833A4/fr active Pending
- 2017-10-19 US US16/343,366 patent/US20190330307A1/en not_active Abandoned
- 2017-10-19 KR KR1020197014056A patent/KR20190071758A/ko not_active Application Discontinuation
- 2017-10-19 CA CA3039066A patent/CA3039066A1/fr active Pending
- 2017-10-19 CN CN201780069411.8A patent/CN109922821A/zh active Pending
- 2017-10-19 SG SG11201903450YA patent/SG11201903450YA/en unknown
- 2017-10-19 IL IL266032A patent/IL266032B2/en unknown
- 2017-10-19 PE PE2019000842A patent/PE20190743A1/es unknown
- 2017-10-19 SG SG10201913301TA patent/SG10201913301TA/en unknown
-
2019
- 2019-04-17 PH PH12019500853A patent/PH12019500853A1/en unknown
- 2019-04-18 CL CL2019001069A patent/CL2019001069A1/es unknown
- 2019-05-17 ZA ZA2019/03105A patent/ZA201903105B/en unknown
- 2019-05-20 CO CONC2019/0005115A patent/CO2019005115A2/es unknown
-
2021
- 2021-12-07 US US17/544,579 patent/US20220332791A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019004651A (es) | 2019-10-09 |
| CN109922821A (zh) | 2019-06-21 |
| IL266032B2 (en) | 2024-06-01 |
| IL266032A (en) | 2019-06-30 |
| SG10201913301TA (en) | 2020-03-30 |
| KR20190071758A (ko) | 2019-06-24 |
| US20190330307A1 (en) | 2019-10-31 |
| US20220332791A1 (en) | 2022-10-20 |
| SG11201903450YA (en) | 2019-05-30 |
| PH12019500853A1 (en) | 2019-12-02 |
| JP2019535675A (ja) | 2019-12-12 |
| CA3039066A1 (fr) | 2018-04-26 |
| CL2019001069A1 (es) | 2019-08-23 |
| EA201990971A1 (ru) | 2019-10-31 |
| EP3528833A1 (fr) | 2019-08-28 |
| CO2019005115A2 (es) | 2019-05-31 |
| PE20190743A1 (es) | 2019-05-27 |
| ZA201903105B (en) | 2023-03-29 |
| JOP20190085A1 (ar) | 2019-04-17 |
| EP3528833A4 (fr) | 2020-11-25 |
| TN2019000119A1 (en) | 2020-10-05 |
| TW201827069A (zh) | 2018-08-01 |
| WO2018075747A1 (fr) | 2018-04-26 |
| CR20190247A (es) | 2019-07-29 |
| AU2017345435B2 (en) | 2021-11-11 |
| AU2017345435A1 (en) | 2019-05-23 |
| TWI826358B (zh) | 2023-12-21 |
| IL266032B1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46585A (fr) | Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib | |
| MA51451A (fr) | Compositions d'acides aminés et méthodes de traitement de maladies hépatiques | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
| MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
| MA51770A (fr) | Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| MA50267A (fr) | Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr) | |
| MA52790A (fr) | Compositions et méthodes de traitement de la thrombopénie immune | |
| MA47504A (fr) | Composés et méthodes de traitement de l'angiocholite biliaire primitive | |
| MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA56412A (fr) | Thérapie par l'arn messager pour le traitement des maladies articulaires | |
| MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
| MA45149A (fr) | Méthodes de traitement de la maladie d'alzheimer | |
| EA201492282A1 (ru) | Антагонистические антигенсвязывающие белки к двум рецепторам и их применение | |
| MA44762A (fr) | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| MA53553A (fr) | Traitement post-chirurgical de la douleur | |
| MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| MA46750A (fr) | Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents | |
| MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
| EA201791901A1 (ru) | Антагонисты рецептора нейрокинина-3 для терапевтического или косметологического лечения излишних жировых отложений на теле | |
| MA49524A (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression |